Hormonal Acne: Root Causes, Hormone Testing, and Evidence-Based Treatment
At a Glance
- Hormonal acne is driven by androgens stimulating sebaceous gland activity; the key conversion is testosterone to DHT via 5-alpha reductase in skin tissue.
- The insulin-IGF-1 axis is as important as androgens in many patients: high glycemic diets and insulin resistance amplify sebum production and inflammatory signaling.
- Characteristic distribution is the lower face, jawline, and chin, with deep cystic lesions that track with the menstrual cycle in women.
- Spironolactone (50-200mg daily) has a Grade A evidence base for hormonal acne in women; spearmint tea shows promising data in two small RCTs.
- Hormone testing (testosterone, DHEA-S, insulin, LH/FSH ratio) should be considered before initiating hormonal treatment, particularly when PCOS is suspected.
Hormonal acne is one of the most commonly mismanaged conditions in dermatology. Patients spend years on topical antibiotics and over-the-counter products that address the surface lesions but not the underlying driver. When the driver is hormonal, topical management alone is a temporary measure. Understanding what is actually happening hormonally changes both the treatment decisions and the realistic expectations for resolution.
This article covers the androgen-sebum pathway, the insulin connection that gets less attention but is equally important, how to test hormones properly, and which treatments have real evidence. For the broader picture of acne management, see our Acne guide.
The Androgen-Sebum Pathway
Sebaceous glands are sensitive to androgens, particularly dihydrotestosterone (DHT), which is produced locally in skin tissue from testosterone via the enzyme 5-alpha reductase (5AR). DHT binds to androgen receptors in sebocytes (sebaceous gland cells) and upregulates sebum production. Excess sebum, combined with abnormal keratinocyte proliferation and Cutibacterium acnes colonization, drives comedone formation and inflammatory lesions.
Importantly, total testosterone levels can be completely normal in women with hormonal acne. The issue is often end-organ sensitivity: sebaceous glands that are hyperresponsive to normal androgen levels because of high local 5AR activity, high androgen receptor density, or elevated DHEA-S driving local DHT conversion. This explains why measuring testosterone alone is insufficient and why patients with “normal” hormone panels can still have hormonally driven acne.
PCOS and Hormonal Acne
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, affecting 6-12% of this population. It is characterized by hyperandrogenism (elevated androgens or clinical signs thereof), ovulatory dysfunction, and polycystic ovarian morphology. Acne, hirsutism, and alopecia are the cardinal dermatological features.
Not all women with hormonal acne have PCOS, and not all PCOS patients have severe acne. But PCOS is worth specifically considering when acne is accompanied by irregular periods, hirsutism, central weight gain, or fertility concerns. A 2011 meta-analysis in the European Journal of Obstetrics and Gynecology (22 studies) found that around 34% of women with PCOS listed acne as a primary complaint, and acne was more severe and more treatment-resistant in PCOS patients than in women with acne without PCOS.
The Insulin-IGF-1 Connection
Insulin and insulin-like growth factor 1 (IGF-1) are independent drivers of hormonal acne, operating in parallel with the androgen pathway. High insulin levels, driven by high glycemic diets, insulin resistance, or PCOS-related insulin dysregulation, stimulate the liver to produce IGF-1. Both insulin and IGF-1 directly stimulate sebocyte proliferation and sebum synthesis. They also suppress sex hormone-binding globulin (SHBG), which increases free (biologically active) testosterone circulating in the blood.
This creates a vicious cycle in PCOS patients: elevated insulin reduces SHBG, raising free testosterone, which worsens hyperandrogenism, which worsens insulin resistance via effects on adipose tissue and muscle. Breaking the insulin component of this cycle is often as important as targeting androgens directly.
Kwon et al. (2012, Acta Dermato-Venereologica, RCT, n=32) randomized acne patients to a low glycemic load diet versus a conventional diet for 10 weeks. The low glycemic group showed significantly greater reductions in total lesion count (51% vs 31%) and non-inflammatory lesion count, along with reductions in free androgen index and IGF-1. This was a small trial but the biological mechanism is well-supported, and the dietary intervention is low-risk.
How to Recognize Hormonal Acne: Clinical Features
The distribution pattern is the most reliable clinical marker. Hormonal acne concentrates on the lower face: jawline, chin, and perioral area. It often spares the forehead and nose, which are more typical of seborrheic or comedonal acne. Lesions are typically deep, cystic, and tender, rather than superficial blackheads or whiteheads. In women, a consistent premenstrual flare pattern (worsening in the week before menstruation) strongly suggests hormonal driving.
In men, hormonal acne is less well characterized but often involves the back and shoulders alongside the face, and may be associated with anabolic steroid use, which dramatically amplifies androgenic signaling in sebaceous tissue.
Hormone Testing: What to Measure and When
Routine hormone testing for all acne patients is not necessary. But testing is worthwhile when acne is moderate-to-severe, treatment-resistant, associated with other signs of androgen excess, or when the patient wants to understand the hormonal picture before committing to pharmaceutical treatment.
Useful baseline tests include: total and free testosterone, DHEA-S (dehydroepiandrosterone sulfate), LH and FSH (and their ratio, which is elevated in PCOS), fasting insulin and fasting glucose (to calculate HOMA-IR), sex hormone-binding globulin, and in some cases prolactin. Thyroid function (TSH, free T4) is worth including because hypothyroidism can worsen acne via IGF-1 pathway interactions.
Testing should be done in the early follicular phase of the menstrual cycle (days 2-5) for most reproductive hormones, as values fluctuate significantly across the cycle. Oral contraceptive use substantially alters baseline hormone levels and ideally testing is done before initiating or after a washout period if feasible.
Evidence-Based Treatments
Spironolactone
Spironolactone is an aldosterone antagonist that also blocks androgen receptors and inhibits 5-alpha reductase. At doses of 50-200mg daily, it is consistently effective for hormonal acne in women. A 2017 Cochrane review of 9 RCTs found that spironolactone significantly reduced acne severity versus placebo, with higher doses producing greater effect.
The most common side effects are irregular menstrual bleeding and breast tenderness, which often resolve after the first few cycles. Hyperkalemia is a theoretical risk that is clinically relevant primarily in patients with renal impairment or those taking ACE inhibitors. In young healthy women, routine potassium monitoring is less necessary than older prescribing guidelines suggested. Spironolactone is teratogenic and requires effective contraception in women of reproductive age.
Oral Contraceptives
Combined oral contraceptives (estrogen plus progestin) reduce hormonal acne by suppressing ovarian androgen production and increasing SHBG, which reduces free testosterone. Four OCPs are FDA-approved specifically for acne: norgestimate/ethinyl estradiol, norethindrone acetate/ethinyl estradiol, drospirenone/ethinyl estradiol, and drospirenone/ethinyl estradiol/levomefolate.
Progestin choice matters considerably. Progestins with high androgenic activity (norgestrel, levonorgestrel, norethindrone at high doses) can worsen acne. Low-androgenic or anti-androgenic progestins (drospirenone, dienogest, cyproterone acetate) are preferable for acne management. Drospirenone in particular has demonstrated anti-mineralocorticoid and anti-androgenic properties that make it among the best progestin choices for acne-prone patients.
Spearmint Tea
Spearmint has anti-androgenic properties. Akdogan et al. (2007, Phytotherapy Research, n=21) found that women with hirsutism who drank two cups of spearmint tea daily for 5 days had significantly reduced free testosterone levels with no change in total testosterone, consistent with SHBG elevation. A follow-up RCT by Grant (2010, Phytotherapy Research, n=42) found that spearmint tea twice daily for 30 days significantly reduced free and total testosterone in women with PCOS and hirsutism.
These studies measured hormone levels in hirsutism patients rather than acne severity directly, and sample sizes are small. But the mechanism is biologically plausible and the intervention is essentially risk-free. Spearmint tea twice daily is a reasonable adjunct for women with mild hormonal acne who prefer to start with non-pharmaceutical approaches.
DIM (Diindolylmethane)
DIM is a compound derived from cruciferous vegetables that promotes the metabolism of estrogen toward less potent 2-hydroxy metabolites and may also modulate androgen metabolism. It is widely used in the integrative medicine world for hormonal acne, particularly in women with estrogen-dominant hormonal patterns.
The clinical evidence in acne is limited to mechanistic studies and case reports. One small pilot study (Zeligs 2001, unpublished) reported improvement in acne with DIM supplementation. DIM is well-tolerated at standard doses (100-200mg daily) but can cause dark urine (from enhanced estrogen metabolism byproducts), which is harmless but alarming to patients if they are not warned.
Zinc
Zinc inhibits 5-alpha reductase activity and has direct anti-inflammatory effects on Cutibacterium acnes-driven inflammation. Multiple RCTs have compared oral zinc (as gluconate or sulfate, 30-90mg elemental zinc daily) to placebo or antibiotics. A 2012 meta-analysis in the Journal of Drugs in Dermatology (13 trials) found that zinc significantly reduced acne lesion counts, with effect sizes smaller than oral antibiotics but clinically meaningful. Zinc is particularly useful as an antibiotic-sparing option or as an adjunct to other treatments.
Low Glycemic Diet
As discussed in the insulin-IGF-1 section, reducing dietary glycemic load consistently reduces acne severity in RCT settings. Practically, this means limiting white bread, white rice, sugary beverages, processed snacks, and other high glycemic foods, and replacing them with whole grains, legumes, vegetables, and protein. Dairy, particularly skim milk, has independent associations with acne severity in observational studies, possibly through IGF-1 content and leucine-driven mTORC1 activation. Trialing dairy reduction is a reasonable step for patients who have not found dietary patterns relevant to their acne.
Retinoids
Topical retinoids (tretinoin, adapalene) and oral isotretinoin address the keratinocyte abnormality and sebum overproduction that hormonal signaling drives. Isotretinoin at standard doses (0.5-1mg/kg/day) reduces sebaceous gland size by up to 90% and is the most effective single treatment for severe hormonal acne. It does not address the hormonal driver directly, which is why acne can recur after isotretinoin in patients with ongoing hormonal triggers. In women with PCOS-driven acne, combining isotretinoin with hormonal treatment (spironolactone or OCP) after the isotretinoin course often produces more durable remission.
Treatment Evidence Summary
| Treatment | Evidence Grade | Key Evidence | Best For |
|---|---|---|---|
| Spironolactone (50-200mg) | Grade A | Cochrane 2017, 9 RCTs | Women with hormonal acne; PCOS-related acne |
| Low glycemic diet | Grade B | Kwon 2012 RCT, n=32 | All hormonal acne; insulin-driven component |
| Anti-androgenic OCP (drospirenone) | Grade A | FDA-approved for acne; multiple RCTs | Women wanting contraception; PCOS |
| Zinc (30-90mg elemental) | Grade B | Meta-analysis 2012, 13 trials | Antibiotic-sparing; adjunct to other treatments |
| Isotretinoin | Grade A | Decades of RCT evidence | Severe, treatment-resistant hormonal acne |
| Spearmint tea (2 cups/day) | Grade C | Grant 2010 RCT, n=42 (hirsutism) | Mild hormonal acne; low-risk adjunct |
| DIM (100-200mg) | Grade D | Mechanistic data; pilot study | Estrogen-dominant hormonal pattern |
When to See an Endocrinologist
Most hormonal acne in women can be managed by a dermatologist or a GP with dermatology experience. An endocrinologist referral is appropriate when: testosterone levels are significantly elevated (above 1.5-2x the upper limit of normal), DHEA-S is markedly elevated (suggesting adrenal pathology), there are signs of Cushing syndrome, or acne fails to respond to standard hormonal treatments and testing suggests a primary endocrine disorder.
PCOS evaluation ideally involves both a dermatologist (for skin manifestations) and a gynecologist or endocrinologist (for the metabolic and reproductive picture). Treating acne in PCOS without addressing insulin resistance and anovulation produces partial results. The insulin resistance itself responds well to lifestyle intervention (low glycemic diet, exercise) and in some cases to metformin, which also improves acne in PCOS patients by reducing androgen production through insulin normalization.
If you have moderate-to-severe acne on the jawline and chin, particularly if it tracks with your cycle or has not responded to standard topical treatment, the hormonal workup described above is worth doing. Understanding your specific hormonal pattern means treatments can be targeted rather than generic, which substantially improves the odds of lasting improvement.
